Advertisement

Discussion

    Published:October 04, 2022DOI:https://doi.org/10.1016/j.surg.2022.07.054
        Dr Naris Nilubol (Bethesda, MD): In the in vivo study, if you compare single drug versus combination, it probably does not have statistical significance in showing lower tumor volume than the control. So, how would you optimize that? Also, a comment, with your pathway activation and decreased mammalian target of rapamycin (mTOR) signaling, you might want to look at autophagy.
        To read this article in full you will need to make a payment

        Purchase one-time access:

        Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
        One-time access price info
        • For academic or personal research use, select 'Academic and Personal'
        • For corporate R&D use, select 'Corporate R&D Professionals'

        Subscribe:

        Subscribe to Surgery
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect